-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract] . Proc Am Assoc Cancer Res 1999 ; 40 : Abstract 301 . 39 Hudes G Carducci M Tomczak P . Temsirolimus
Search Results
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
Matthew G. Fury and David G. Pfister
and related compounds (e.g., everolimus, temsirolimus) that inhibit the serine/threonine kinase activity of mTOR in the mTORC1 compex, 65 Temsirolimus reduces growth of HNSCC cell lines in xenograft models, 66 and everolimus inhibits tumor growth in
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
favorable side effect profile. 49 , 52 Six different targeted therapy medications have been approved by the FDA for the treatment of patients with advanced RCC: sunitinib, sorafenib, pazopanib, temsirolimus, everolimus, and bevacizumab combined with
Rashmi Chugh
translation. 56 Multiple studies are examining the role of mTOR inhibition in sarcomas. The Sidney Kimmel Comprehensive Cancer Center is conducting a phase I/II study to evaluate the safety and efficacy of temsirolimus and liposomal doxorubicin in patients
Barbara Burtness
as sorafenib and vemurafenib, have been associated with hand-foot skin reaction (HFSR), 5 and the newer BRAF inhibitor regorafenib “has some pretty dramatic skin manifestations,” noted Dr. Burtness. mTOR inhibitors, such as temsirolimus and
Eric Jonasch
bevacizumab, high-dose interleukin-2 for selected patients, and temsirolimus. Ipilimumab plus nivolumab was just added to the NCCN Guidelines as a category 2A recommendation for subsequent therapy in patients with metastatic RCC. Best supportive care is
Diane L. Reidy-Lagunes
have been implicated as critical pathways in NET growth. In a phase II trial, 36 heavily pretreated patients with disease progression (21 carcinoid, 15 pancNET) were treated with 25 mg intravenous weekly doses of the mTOR inhibitor temsirolimus, with an
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Featured Updates to the NCCN Guidelines
Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, CGC, Lydia J. Hammond, and Griselda Zuccarino-Catania
the next era. Currently recommended first-line targeted therapy options in the NCCN Guidelines are single-agent TKIs or VEGF inhibitors, including pazopanib, 29 sunitinib, 30 axitinib, 31 and cabozantinib, 32 or temsirolimus, which targets mTOR. 33
Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim
default standard for comparison in first-line trials that led to the approval of 3 targeted agents in RCC, 6 , 9 , 24 including the phase III trials of sunitinib and temsirolimus. Because of the improved progression-free survival seen in the experimental
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ernest U. Conrad III, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian Scavone
-inhibitor that has been successful in treating ALK-rearranged non–small cell lung cancer. 126 mTOR inhibitors such as sirolimus, temsirolimus, and everolimus have also shown promising results in patients with metastatic perivascular epithelioid cell tumors and
